Reviewer's report

Title: Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Version: 3  Date: 11 June 2015

Reviewer: Mark Burkard

Reviewer's report:

Major Compulsory Revisions:
(a) Remove conclusions no efficacy in abstract and conclusion. This case report cannot assess efficacy. Similarly the claims on safety should be tempered because a case report only provides limited safety evidence (that it is safe in some people, without defining what fraction).
(b) Minor essential revisions:
"Degree I thrombocytopenia, degree III leukopenia" in abstract and p7 L7 appear to refer to grade. Should describe them as grade 1, grade 3 and provide the grading criteria (e.g. NCI CTCAE v4).
p5 L13 should read "hemodialysis every 48 hours, and has produced no urine"
p8 L2 "Marion et al." should read Haubitz et al.
p8 L12 "as an implosive therapy" doesn't make sense. Suggest you restate.
p8 L26-27 per cyclophosphamide package insert the hemodialysis may or may not clear this drug depending on the particular type. If you are going to talk about how it effects cyclophosphamide clearance, it would be important to know details of the hemodialysis methods.

Level of interest: An article of limited interest

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No competing interests